Sun Pharma rises on plan to raise QIP worth Rs 12,000 crore

15 Sep 2014 Evaluate

Sun Pharmaceutical Industries is currently trading at Rs. 809.00, up by 3.10 points or 0.38% from its previous closing of Rs. 805.90 on the BSE.

The scrip opened at Rs. 804.85 and has touched a high and low of Rs. 815.00 and Rs. 804.85 respectively. So far 97750 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 877.40 on 03-Sep-2014 and a 52 week low of Rs. 535.55 on 18-Sep-2013.

Last one week high and low of the scrip stood at Rs. 872.00 and Rs. 789.00 respectively. The current market cap of the company is Rs. 167764.28 crore.

The promoters holding in the company stood at 63.65% while Institutions and Non-Institutions held 28.05% and 8.29% respectively.

Sun Pharmaceutical Industries, India’s largest drug maker by value, is planning to raise Rs 12000 crore through qualified institutional placement (QIP) route. In this regard, the company is seeking shareholders’ approval at its 27th annual general meeting to be held by the end of September.

Last year, there were reports that Sun Pharma was in talks to buy Sweden's Meda AB for a sum between $5 billion and $6 billion, to boost its generics business in developed markets.

Recently, the surprise inspection took place due to an increased number of recalls from the plant. Sun Pharma recalled 40,000 bottles of Venlafaxine Hydrochloride extended-release tablets, Gemcitabine and Metformin, manufactured at Halol from the US market in past few months.

 

Peers
Company Name CMP
Sun Pharma Inds. 1515.15
Dr. Reddys Lab 6277.10
Cipla 1388.00
Zydus Lifesciences 980.65
Lupin 1610.55
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.